Subsequent in vivo VCAM-1–targeted imaging studies demonstrated that, despite no evident gadolinium contrast enhancement, VCAM-MPIO induced hypointensities were clearly visible in the brain metastasis model and revealed areas of tumor that were also not detectable by the alternative conventional clinical method of T2-weighted MRI. The gene discussed is VCAM1; the disease is neoplasm.